Phenylephrine for Syncope

Phase-Based Progress Estimates
Syncope+5 More
Phenylephrine - Drug
< 65
All Sexes
What conditions do you have?

Study Summary

This trial will study the effects of a simple molecule, nitric oxide, on people with vasovagal syncope (simple postural faint) or postural tachycardia syndrome (POTS).

Eligible Conditions
  • Syncope
  • Vasovagal Syncope
  • Marijuana Abuse

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Syncope

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion
Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP)

Trial Safety

Safety Progress

1 of 3

Other trials for Syncope

Trial Design

1 Treatment Group

Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)
1 of 1
Experimental Treatment

90 Total Participants · 1 Treatment Group

Primary Treatment: Phenylephrine · No Placebo Group · Phase < 1

Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)Experimental Group · 2 Interventions: Phenylephrine, L-Ng-monomethyl Arginine (L-NMMA) · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
65 Previous Clinical Trials
5,594 Total Patients Enrolled
2 Trials studying Syncope
75 Patients Enrolled for Syncope
Julian M. Stewart, M.D., Ph.D.Principal InvestigatorNew York Medical College
1 Previous Clinical Trials
51 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a headache.\n
You have exercise intolerance.
You have sweating heat.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.